BioCentury | Apr 25, 2005
Clinical News

EntreMed preclinical data

...In a mouse model of chronic rheumatoid arthritis, proteinase activated receptor (PAR) 2 antagonist completely blocked the development of arthritis...
BioCentury | Apr 25, 2005
Clinical News

EntreMed preclinical data

In a mouse model of angiogenesis, proteinase activated receptor (PAR) 2led to >80% dose-dependent inhibition of angiogenesis. Data were presented at the American Association of Cancer Research meeting in Anaheim. EntreMed Inc. (ENMD), Rockville, Md....
BioCentury | Apr 25, 2005
Clinical News

EntreMed preclinical data

...In a mouse model of renal carcinoma tumor, proteinase activated receptor (PAR) 2 inhibited tumor growth by 70%. Data were...
BioCentury | Dec 15, 2003
Clinical News

EntreMed preclinical data

In a mouse model of angiogenesis, PAR-2 antagonists inhibited angiogenesis in a dose-dependent manner, reaching >75% at the highest doses. In a mouse model of metastatic lung cancer, two PAR-2 antagonists showed >75% inhibition of...
BioCentury | Dec 3, 2001
Company News

Patologia Univesita di Perugia other research news

Researchers published in the Proceedings of the National Academy of Sciences that SLIGRL-NH2 treatment significantly reduced the 7-day mortality and increased clinical IBD scores compared to a control peptide in a mouse model of IBD...
BioCentury | Jul 2, 2001
Company News

J&J other research news

Researchers at JNJ's R.W. Johnson Pharmaceutical Research and colleagues published in Nature Medicine that local injection of rats' paws with sub-inflammatory doses of PAR2 agonists decreased the pain threshold to thermal insult. The PAR2 agonist-induced...
BioCentury | Feb 14, 2000
Company News

University of California other research news

UCSF researchers and colleagues published in Nature Medicine that cleavage of PAR2 on spinal neurons by the proteases trypsin and mast cell tryptase induces the release of proinflammatory neuropeptides . They suggest that the same mechanism...
Items per page:
1 - 7 of 7